High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...
A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...
The cells of all animals—including humans—are characterized by their ability to adhere particularly well to surfaces in their environment. This mechanically stable adhesion enables the development of ...
The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...
Young minds are easily molded. Each new experience rewires a child's brain circuitry, adding and removing synaptic ...
CCN1 is a key factor for stabilizing brain circuits in adulthood, offering a therapeutic target for conditions, such as Alzheimer's and PTSD.
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...
As of Thursday, December 11, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 8.38%, which has investors questioning if this is right time to sell.
Learn more about whether Protagonist Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
New research shows how CCN1, a protein secreted by astrocytes, is critical for stabilizing neural circuits in adulthood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback